Anteris Technologies Ltd
ASX:AVR

Watchlist Manager
Anteris Technologies Ltd Logo
Anteris Technologies Ltd
ASX:AVR
Watchlist
Price: 9.3 AUD -3.93% Market Closed
Market Cap: 196.6m AUD
Have any thoughts about
Anteris Technologies Ltd?
Write Note

Anteris Technologies Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Anteris Technologies Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Anteris Technologies Ltd
ASX:AVR
Common Stock
AU$283m
CAGR 3-Years
27%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Common Stock
AU$114.5m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
4%
Polynovo Ltd
ASX:PNV
Common Stock
AU$191.6m
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
7%
SDI Ltd
ASX:SDI
Common Stock
AU$12.9m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Ansell Ltd
ASX:ANN
Common Stock
$1B
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
-2%
Next Science Ltd
ASX:NXS
Common Stock
$133.8m
CAGR 3-Years
10%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

Anteris Technologies Ltd
Glance View

Market Cap
178.8m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.76 AUD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Anteris Technologies Ltd's Common Stock?
Common Stock
283m AUD

Based on the financial report for Dec 31, 2023, Anteris Technologies Ltd's Common Stock amounts to 283m AUD.

What is Anteris Technologies Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
15%

Over the last year, the Common Stock growth was 34%. The average annual Common Stock growth rates for Anteris Technologies Ltd have been 27% over the past three years , 15% over the past five years .

Back to Top